At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SXTP 60 degrees pharmaceuticals, Inc.
Market Closed 11-22 16:00:00 EST
0.9000
+0.0260
+2.97%
盘后0.9000
+0.00000.00%
18:51 EST
High0.9500Low0.8610Vol34.69K
Open0.9500D1 Closing0.8740Amplitude10.18%
Mkt Cap1.68MTradable Cap1.33MTotal Shares1.86M
T/O31.53KT/O Rate2.34%Tradable Shares1.48M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
H.C. Wainwright Reaffirms Their Hold Rating on 60 Degrees Pharmaceuticals, Inc. (SXTP)
TIPRANKS  ·  11-16
H.C. Wainwright Reaffirms Their Hold Rating on 60 Degrees Pharmaceuticals, Inc. (SXTP)
60 Degrees Pharmaceuticals Inc. (SXTP) Reports Q3 Loss, Misses Revenue Estimates
Zacks  ·  11-15
60 Degrees Pharmaceuticals Inc. (SXTP) Reports Q3 Loss, Misses Revenue Estimates
BRIEF-60 Degrees Pharmaceuticals Posts Q3 Loss of 93 cents
Reuters  ·  11-15
BRIEF-60 Degrees Pharmaceuticals Posts Q3 Loss of 93 cents
60 Degrees Q3 2024 GAAP EPS $(0.93) Misses $(0.70) Estimate, Sales $135.00K Miss $242.00K Estimate
Benzinga  ·  11-15
60 Degrees Q3 2024 GAAP EPS $(0.93) Misses $(0.70) Estimate, Sales $135.00K Miss $242.00K Estimate
60 Degrees Pharmaceuticals Inc: Qtrly Loss per Share $0.93
THOMSON REUTERS  ·  11-15
60 Degrees Pharmaceuticals Inc: Qtrly Loss per Share $0.93
60 Degrees Pharmaceuticals Announces Third Quarter 2024 Results
THOMSON REUTERS  ·  11-15
60 Degrees Pharmaceuticals Announces Third Quarter 2024 Results
Press Release: 60 Degrees Pharmaceuticals Announces Third Quarter 2024 Results
Dow Jones  ·  11-15
Press Release: 60 Degrees Pharmaceuticals Announces Third Quarter 2024 Results
60 Degrees Pharmaceuticals Inc. Announces Arakoda® Promotional Pilot in Advance of Expanded U.S. Launch
THOMSON REUTERS  ·  10-03
60 Degrees Pharmaceuticals Inc. Announces Arakoda® Promotional Pilot in Advance of Expanded U.S. Launch
60 Degrees Pharmaceuticals Inc. Announces ARAKODA® Promotional Pilot in Advance of Expanded U.S. Launch
GlobeNewswire  ·  10-03
60 Degrees Pharmaceuticals Inc. Announces ARAKODA® Promotional Pilot in Advance of Expanded U.S. Launch
H.C. Wainwright Reaffirms Their Hold Rating on 60 Degrees Pharmaceuticals, Inc. (SXTP)
TIPRANKS  ·  09-13
H.C. Wainwright Reaffirms Their Hold Rating on 60 Degrees Pharmaceuticals, Inc. (SXTP)
60 Degrees Pharmaceuticals Closes $4 Million Private Placement
MT Newswires Live  ·  09-06
60 Degrees Pharmaceuticals Closes $4 Million Private Placement
60 Degrees Pharmaceuticals, Inc. Announces Closing of $4 Million Private Placement Priced at-the-Market Under Nasdaq Rules
THOMSON REUTERS  ·  09-06
60 Degrees Pharmaceuticals, Inc. Announces Closing of $4 Million Private Placement Priced at-the-Market Under Nasdaq Rules
BRIEF-60 Degrees Pharmaceuticals Announces $4 Mln Private Placement
Reuters  ·  09-04
BRIEF-60 Degrees Pharmaceuticals Announces $4 Mln Private Placement
60 Degrees Pharmaceuticals to raise $4M via private placement; shares fall
seekingalpha  ·  09-04
60 Degrees Pharmaceuticals to raise $4M via private placement; shares fall
60 Degrees Pharmaceuticals, Inc. Announces $4 Million Private Placement Priced at-the-Market Under Nasdaq Rules
THOMSON REUTERS  ·  09-04
60 Degrees Pharmaceuticals, Inc. Announces $4 Million Private Placement Priced at-the-Market Under Nasdaq Rules
60 Degrees Pharmaceuticals, Inc. Announces $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules
GlobeNewswire  ·  09-04
60 Degrees Pharmaceuticals, Inc. Announces $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules
60 Degrees Pharmaceuticals, Inc. Regains Compliance With Nasdaq Listing Requirements
THOMSON REUTERS  ·  08-29
60 Degrees Pharmaceuticals, Inc. Regains Compliance With Nasdaq Listing Requirements
60 Degrees Pharmaceuticals, Inc. Regains Compliance with Nasdaq Listing Requirements
GlobeNewswire  ·  08-29
60 Degrees Pharmaceuticals, Inc. Regains Compliance with Nasdaq Listing Requirements
60 Degrees Pharmaceuticals Second Quarter 2024 Earnings: Misses Expectations
Simply Wall St.  ·  08-17
60 Degrees Pharmaceuticals Second Quarter 2024 Earnings: Misses Expectations
60 Degrees Pharmaceuticals GAAP EPS of -$4.23
seekingalpha  ·  08-15
60 Degrees Pharmaceuticals GAAP EPS of -$4.23
No data available

Introduction

Company Name.
60 degrees pharmaceuticals, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. 60 Degrees Pharmaceuticals, Inc. was founded in 2010 and is based in Washington, District Of Columbia.
Issue price:
--